Evidence map›Paper›PMID 42611136›Full record

ReviewJournal of computer-aided molecular design2026

A survey of transformer and LLM-based architectures, workflows, and systems in drug discovery.

Stefanos Tsimenidis, Eleni Vrochidou, George A Papakostas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Stefanos TsimenidisMLV Research Group, Department of Informatics, Democritus University of Thrace, 65404, Kavala, Greece. stsimeni@cs.duth.gr.ORCID 0009-0005-3846-3726
Eleni VrochidouMLV Research Group, Department of Informatics, Democritus University of Thrace, 65404, Kavala, Greece.ORCID 0000-0002-0148-8592
George A PapakostasMLV Research Group, Department of Informatics, Democritus University of Thrace, 65404, Kavala, Greece.ORCID 0000-0001-5545-1499

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug discovery has greatly benefited from the recent progress in Artificial Intelligence (AI). Numerous tasks within pharmaceutical research and development are being formulated as classification, regression, generation, or sequence-to-sequence problems, and tackled via AI systems that can learn from data, making the process of discovery and screening faster and more efficient. Two of the greatest breakthroughs in AI have arguably been the advent of transformers and Large Language Models (LLMs). With their parallel processing capabilities, their ability to detect dependencies and interactions in sequence data, and the vast knowledge stored in their millions or billions of parameters, transformers and LLMs are successful, highly popular additions to the computational drug discovery arsenal. This work provides an extensive overview of transformer-based architectures and workflows utilized in drug discovery. The conducted analysis focuses on the types of transformers and LLMs currently in use, as well as the systems and workflows that integrate them. Research findings indicate the transformer architecture's exceptional flexibility and adaptability, which support its implementation across diverse configurations and systems. This versatility positions it as a transformative model with the promising potential to revolutionize drug discovery and drive significant scientific breakthroughs.

Indexed as

Artificial IntelligenceDrug DiscoveryHumansLarge Language ModelsWorkflowArtificial intelligenceDrug discoveryLarge language modelsTransformer architecture

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.